Board of Directors

Anna Malm Bernsten

Anna Malm Bernsten

Born: 1961. Title: Chairman of the Board. Member of the Board since 2006. Member of the Audit Committee and the R&D Committee.
Education: M.Sc. in Engineering.
Background: M.Sc. in Engineering with an extensive knowledge of the life sciences sector. Runs own consult­ancy firm operating in the fields of leader­ship strategy and busi­ness deve­lopment. Experience of senior posi­tions with, amongst others, GE Healthcare Life Sciences, Pharmacia, Assa Abloy, Medivir and Baxter Medical. Former President & CEO of Carmeda AB.
Other directorships: Chairman of the Boards of CEBA AB and Oatly AB. Member of the Boards of Cella­vision, Pågen­gruppen and Björn Axén. Former Member of the Board of Bio­Phausia AB.
Shares in Medivir: 1,224 class B shares.

Anders Ekblom

Born: 1954. Title: Member of the Board since 2014. Member of the R&D Committee and the Audit Committee.
Education: Doctor of Medicine and Associate Pro­fes­sor in physio­logy at the Karo­linska Insti­tute.
Background: Physician (specialising in anaesthesia and intensive care), dentist.
Other director­ships: Chairman of the Boards of the Karo­linska Uni­ver­sity Hos­pital and TFS Inter­national AB, Member of the Boards of the Swedish Re­search Council, SwedenBio, AnaMar AB, Infant Bacterial Therapeutics AB, Mereo Bio­pharma Ltd, RSPR Pharma AB, Visco­gel AB, Alligator Biosciences and a senior advisor to Phase4 Partners, UK.
Shares in Medivir: 1,345 class B shares.

Anders Hallberg

Anders R Hallberg

Born: 1945. Title: Member of the Board since 2012. Chairman of the R&D Committee.
Education: Professor of Medicinal Chemistry at Uppsala University’s Faculty of Pharmacy.
Background: Held a number of posi­tions as a scien­tific advisor at Astra Zeneca and smaller pharma­ceutical compa­nies between 1990 and 2006. Prior to this, he was the Head of the Medicinal Chemistry Depart­ment at Astra in Lund. Vice-Chan­cellor of Uppsala University between 2006 and 2011. He has publi­shed over 270 scien­tific articles, a large number of which are on the subject of pharma­ceuticals for the treat­ment of infec­tious diseases, and co-inventor of a large number of granted patents. Member of the Royal Swedish Academy of Sciences, and the Royal Swedish Academy of Engi­neering Sciences. Awarded honorary docto­rates in Sweden and other countries.
Other directorships: Member of the Boards of foundations and universities.
Shares in Medivir: 1,030 class B shares.

Bengt Julander

BENGT JULANDER

Born:1953. Title: Member of the Board since 2017.
Education: Pharmacist. Has worked in the pharmaceutical industry since 1978.
Background: CEO of Linc AB, which invests in life sciences. Since 1990, primarily active as an investor in and a Member of the Boards of pharmaceutical development companies. Experience of developing and commercialising products.
Other directorships: Member of the Boards of Bringwell AB, Linc AB, Livland Skog AB, Pharmalink AB, Proequo AB, Sedana Medical AB, Stille AB and Swevet AB, and a number of smaller companies.
Shares in Medivir: 1,117,450 class B shares (through companies).

Helena Levander

Born: 1957. Title: Member of the Board since 2015. Member of the Remu­neration Commit­tee and Chairman of the Audit Committee.
Education: B.Sc. in Economics and Business Admini­stration from the Stock­holm School of Eco­nomics.
Background: Exten­sive expe­rience of the financial and equity markets and of corpo­rate gover­nance issues. Previous employed by Neonet, Odin För­valt­ning, Nordea Asset Manage­ment and SEB Asset Manage­ment, amongst others.
Other director­ships: Founder and now Chairman of the Board of Nordic Investor Services AB. Member of the Boards of Concordia Maritime A, Hans Andersson Recycling AB and Collector AB.
Shares in Medivir, including family: 5,250 class B shares.

BENGT WESTERMARK

Born: 1945. Title: Member of the Board since 2017.
Education: Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986.
Background: Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences. He has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers.
Other directorships: Member of the Board of Hamlet Pharma AB and a variety of advisory groups for medical research financing.
Shares in Medivir: 0.

Employee representative

Stina Lundgren

Born: 1979. Title: Member of the Board, appointed by the Unionen trade union, since 2013.
Background: Ph.D. in Chemistry from KTH Royal Institute of Technology. Employed in 2008 as a Senior Research Scientist and team leader in the Chemistry Department.
Shares in Medivir: 1,338 class B shares.

Page updated 20 June 2017